Janux Therapeutics’ Post

Learn how Sona’s THT therapy achieved a vaccine effect, inhibiting the growth of secondary melanoma tumors in their preclinical efficacy study by joining us for a webinar today at 3 pm EDT for a discussion about Sona’s melanoma data from its current preclinical efficacy study of Sona's innovative cancer treatment therapy, Targeted Hyperthermia Therapy (THT). This is your opportunity to discover how Sona's THT therapy, when paired with conventional immunotherapies, could revolutionize certain cancer treatment outcomes. Register here: https://bit.ly/3RClyTW #oncologyresearch #ImmuneSystemActivation #Immunotherapies #stockmarketnews #Cancer #medicaltechnology

#ESMO24 - Day 3 Episode Day three of ESMO - European Society for Medical Oncology Congress had many exciting trials in the #genitourinarycancer space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy. They investigate biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma. While ESMO is finishing, and everyone is jet-setting home, this congress raises many more questions than answers - see you all in Berlin 2025... https://lnkd.in/gCS6fXV8 DV001 (Disitamab vedotin (DV) + pembrolizumab in treatment-naïve HER2-expressing LA/met UC) EV-302 - nectin four expression UpFrontPSMA Study Splash Study (Lu-PNT2002)

The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer, reiterating the need for a more accurate population selection in clinical trials. Read Viewpoint in #Med. https://lnkd.in/eEK5VPMV #lungcancer #clinicaltrial #tiragolumab #TIGIT #SKYSCRAPER-02

LB1410, Keytruda+anti-Tim-3, bispecific antibody, in phase Ib study, today, achieved another important results, PR (-38.3% in second tumor assessment) for a cancer patient prior treated and progressed by: nab-paclitaxel + cisplatin +/-Apatinib; Carboplatin + Apatinib; and anti-PD-1 + Carboplatin + Apatinib for 13 months. We are keeping to show LB1410's efficacy in anti-PD-1 resistant (acquired) cancer patients.

Highly recommended this webinar relevant for any one involved in the treatment of patients with lung cancer. Learn everything about drug-drug interactions, the pros and cons of TDM, and management of toxicity, including discussion of ESMO - European Society for Medical Oncology guidelines. You are all welcome!!

That’s a wrap – thank you American Society of Clinical Oncology (ASCO)! During #ASCO2024, we presented data on mRNA-4157 (V940), our investigational individualized neoantigen therapy, which is being evaluated in a comprehensive development program with our partner Merck. We have initiated Phase 3 studies in patients with high-risk #melanoma and non-small cell lung cancer, in addition to Phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a Phase 2/3 study for cutaneous squamous cell #carcinoma. The future of #cancer treatment is evolving, and #mRNA is at the forefront. Together, we can revolutionize oncology.

Some guidance on the management of adverse events with sotorasib in KRAS G12C NSCLC Lung Cancer Journal - Stephen Liu MedStar Georgetown University Hospital https://lnkd.in/dP_7-FKb #Cancer #LungCancer #NSCLC #OncoDaily #Oncology #CancerResearch #CancerTherapy

Precision Over Power: The Rise of Chemotherapy-Free Treatments in Lung Cancer 🌟 Lung cancer is not just a diagnosis; it's a profound battle that affects patients and their loved ones in unimaginable ways. As traditional chemotherapy often brings harsh side effects, a new era is emerging with chemotherapy-free, targeted therapies offering hope for better outcomes and quality of life. In my latest article, I explore these groundbreaking advancements, particularly in treating EGFR-mutated NSCLC, and how new combinations like RYBREVANT® plus LAZCLUZE™ are redefining the fight against lung cancer. Read on to discover how these innovative treatments are paving the way for a future where precision triumphs over power. 💊🔬 #LungCancer #Oncology #PrecisionMedicine #TargetedTherapies #HealthcareInnovation #EGFR #CancerTreatment #Pharma #MedicalResearch

🎗️ 📢 Prostate Cancer Awareness Month📢🎗️ September 1st marked the start of Prostate Cancer Awareness Month. This month serves as a crucial reminder of the importance of understanding Prostate Cancer. Becoming aware of the risks and symptoms of Prostate Cancer could lead to earlier diagnosis and more effective treatments. Throughout this month, Verity Pharmaceuticals will be sharing valuable insights, facts, and resources on Prostate Cancer. Stay tuned to our page so you don’t miss a post! #MensHealth #ProstateCancerAwareness #PCAM #ProstateCancer